Brain Metastases Pipeline 2025 explores the evolving landscape of investigational therapies, emerging clinical trials, and innovative approaches that are reshaping patient treatment paradigms globally.

DelveInsight's, "Brain Metastases Pipeline Insights 2025" report provides comprehensive insights about 40+ Brain Metastases companies and 45+ pipeline drugs in Brain Metastases pipeline landscape. It covers the Brain Metastases pipeline drug profiles, including clinical and nonclinical stage products. Brain Metastases pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Brain Metastases Pipeline Outlook Report- https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Brain Metastases Pipeline Report
• In August 2025, Grupo Español Multidisciplinar de Melanoma announced a Phase II clinical trial designed to evaluate the activity of encorafenib plus binimetinib followed by cemiplimab and fianlimab in patients with BRAF mutated melanoma and symptomatic brain metastases, following the simon design Two-stage minimax.
• In August 2025, Stemline Therapeutics Inc. conducted a study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in patients with active brain metastases from ER-positive, HER-2 negative breast cancer.
• DelveInsight's Brain Metastases pipeline report depicts a robust space with 40+ active players working to develop 45+ pipeline therapies for Brain Metastases treatment.
• The leading Brain Metastases Companies such as HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.
• Promising Brain Metastases Pipeline Therapies such as GLIADEL, 18F fluciclovine, Pembrolizumab, IPILIMUMAB, Cabozantinib, Trastuzumab, capecitabine, lapatinib, Lenvatinib and others.

Learn how leading Brain Metastases Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Brain Metastases Clinical Trials Assessment- https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Brain Metastases Emerging Drugs Profile
• ANG1005: Angiochem
ANG1005 is a novel targeted taxane derivative that is the first oncology product to leverage Angiochem's technology platform to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 is an Angiopep-2 paclitaxel conjugate that gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain.

• Azeliragon: Cantex Pharmaceuticals, Inc.
Azeliragon, is an oral, small molecule, administered once-daily, that inhibits RAGE interactions with its natural ligands, including HMGB1 and S100 proteins, in the tumor microenvironment. Activation of RAGE by these ligands stimulates cancer and its progression and metastasis and resistance to cancer treatment.

• AZD3759: Alpha Biopharma Ltd.
Zorifertinib (AZD3759) is a type of reversible new generation EGFR TKI, which has a strong ability to penetrate the bloodstream, cerebrospinal fluid, and can reach blood volume in the tissue. It is currently investigated for brain metastases and completed Phase II/III trial in July 2022.

The Brain Metastases Pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Brain Metastases with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Brain Metastases Treatment.
• Brain Metastases Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Brain Metastases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Brain Metastases market.

From early-stage research to late-phase Brain Metastases Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ Brain Metastases Treatment Drugs- https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Brain Metastases Companies
HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.

Brain metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Brain Metastases Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Stay updated with the latest Brain Metastases Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Brain Metastases Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Brain Metastases Pipeline Report
• Coverage- Global
• Brain Metastases Companies- HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.
• Brain Metastases Pipeline Therapies- GLIADEL, 18F fluciclovine, Pembrolizumab, IPILIMUMAB, Cabozantinib, Trastuzumab, capecitabine, lapatinib, Lenvatinib and others.
• Brain Metastases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Brain Metastases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Brain Metastases Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Brain Metastases Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Brain metastases: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Brain metastases- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. ANG1005: Angiochem
9. Mid Stage Products (Phase II)
10. Paxalisib: Kazia Therapeutics
11. Early Stage Products (Phase I)
12. MW151: ImmunoChem Therapeutics, LLC
13. Preclinical and Discovery Stage Products
14. JBI-2174: Jubilant Therapeutics
15. Inactive Products
16. Brain metastases Key Companies
17. Brain metastases Key Products
18. Brain metastases- Unmet Needs
19. Brain metastases- Market Drivers and Barriers
20. Brain metastases- Future Perspectives and Conclusion
21. Brain metastases Analyst Views
22. Brain metastases Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.